To be able to find the right path for the introduction of a medicine in Italy, it is necessary to explore and translate the map of the regulatory environment, identifying and analysing the expectations and reports of decision-makers.
We assist those who turn to us in understanding and obtaining a fair price and reimbursement for a medicine. Finding a common ground, by appropriately mediating between Company profit, patient needs and the limited resources of the National Health Service, is a victory for all interest groups involved.
Through the years, we have learnt that the reality of things is more complex than whatever had been planned.
Even when everything is well-prepared and strategies corresponding to the value of the medicine, in accordance with the regulatory objectives of the agencies, and accommodating to drug governance guidelines, are proposed, the pathway to the authorisation of a medicine may well progress differently than expected. Not to mention any external variables that could slow down, if not hinder, the access of a medicine to the market.
Integrated skills are needed to help with navigation
Though quite detailed, the map we have provided cannot define the complexity of the terrain. Our experience comes to the aid when it is not clear.
L’8 luglio 2025 si è insediato il nuovo Consiglio Superiore di Sanità (CSS), massimo organo tecnico consultivo del Ministero della Salute, in carica per ...
Analysis by Pharma Value A unified approach to innovativeness designation: removing the conditional/full distinction The 2025 Budget Law extends access to the ...
Il 12 luglio 2025, AIFA ha pubblicato il documento sui “Criteri di valutazione per l’attribuzione dell’innovatività terapeutica e sulla gestione degli agenti ...
Il 3 luglio 2025 si è tenuta l’Assemblea Farmindustria dal titolo “Trasformazione globale, life sciences strategy e industria farmaceutica, Futuro e Competitività ...
Il Rapporto 2024 dell’AIFA analizza le attività promozionali dei medicinali rivolte agli operatori sanitari, offrendo una panoramica dettagliata sui volumi gestiti, le modalità di ...
Il 18 marzo 2025, l’Agenzia Europea dei Medicinali (EMA) e la rete dei rappresentanti delle agenzie regolatorie europee (HMA) hanno pubblicato la versione ...
Manage Cookie Consent
We use cookies to optimise our website and services.
Functional
Always active
Technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
Technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
Technical archiving or access that is used exclusively for statistical purposes.Technical storage or access is used solely for anonymous statistical purposes. Without a subpoena, voluntary compliance by your Internet Service Provider, or additional records from third parties, information stored or retrieved for this purpose alone cannot usually be used for identification purposes.
Marketing
Technical storage or access is necessary to create user profiles to send advertisements, or to track the user on one website or several websites for similar marketing purposes.
